Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors
- Registry ID
- EUCTR2011-005471-17
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Klinikum der Universität München-Großhadern
- Start date
- 2012-05-08
- Completion date
- 2017-02-01
- Last update
- 2026-08-16
Conditions
- metastatic pancreatic carcinoma
Summary
1-year survival rate of "good risk" patients who develop Rash under treatment with gemcitabine/erlotinib
Locations
View on source registry